Avanos Medical (AVNS) Cost of Revenue (2013 - 2026)

Avanos Medical has disclosed Cost of Revenue across 14 years of filings, most recently posting $88.0 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 13.26% year-over-year to $88.0 million; the TTM figure through Mar 2026 stood at $357.6 million (up 14.29% YoY), while the FY2025 annual figure was $347.3 million, up 13.31% from the prior year.
• Cost of Revenue came in at $88.0 million for Q1 2026 at Avanos Medical, down from $94.9 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $94.9 million in Q4 2025 to a low of $67.9 million in Q1 2023.
• Average Cost of Revenue over 5 years is $79.2 million, with a median of $77.7 million recorded in 2025.
• The largest YoY upside for Cost of Revenue was 2148.57% in 2022 against a maximum downside of 30.7% in 2022.
• Over 5 years, Cost of Revenue stood at $78.7 million in 2022, then declined by 0.51% to $78.3 million in 2023, then grew by 4.21% to $81.6 million in 2024, then climbed by 16.3% to $94.9 million in 2025, then decreased by 7.27% to $88.0 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $88.0 million in Q1 2026, $94.9 million in Q4 2025, and $91.8 million in Q3 2025.